Photo of Kellie Jones Weddle
Kellie Jones Weddle
Clinical Professor of Pharmacy Practice
Phone: 317-948-5331
Fax: 317-880-0568
E-mail: jones27@purdue.edu
Education
1998 PharmD, University of Kentucky 1997 BS, Pharmacy, University of Kentucky 1993 Associate of Arts, St. Catharine College
Research

VTE Rates in Cancer Patients with COVID-19 Infections. 2020

Incidence and Severity of Acute Kidney Injury (AKI) in Patients with Head and Neck Cancer Receiving Weekly Cisplatin with Radiotherapy (RAISe-AKI). 2019

Safety and efficacy of direct oral factor Xa inhibitors in preventing recurrent venous thromboembolisum in cancer patients. 2018

Retrospective Review of Adult Patients with Solid Tumor Cancers Receiving Rivaroxaban Therapy:Assessment of Associated Bleeding Risks. 2016

Retrospective review of ifosfamide associated encephalopathy for patients admitted to the inpatientoncology unit at the Indianapolis University (IU) Health, University Hospital, Simon Cancer Center. 2016

Compliance with 2010 Infectious Diseases Society of America (IDSA) neutropenic fever guidelines amongpatients with fever and neutropenia. 2012

Retrospective review of pharmacologic and non-pharmacologic risk factors influencing risk of patient falls in an inpatient oncology setting. 2011 

An Oncology Focused Clinical and Research Experience in Eldoret, Kenya.  SAIL Grant Award Winner. Purdue University 2011.

Retrospective review of success rates and toxicities of intraperitoneal chemotherapy for ovarian cancer compared to the published standard of care for intraperitoneal chemotherapy. 2010

Evaluation of the addition of premedications to carboplatin to prevent hypersensitivity reactions in ovarian cancer patients. 2007-2009   

Evaluation of residual toxicity and time to recurrence following intraperitoneal chemotherapy for the treatment of ovarian cancer. 2008
Patient satisfaction with chemotherapy education in academic vs. community setting. 2006-2007

Retrospective chart review of breast cancer patients followed by an anticoagulation management service (AMS): quality assessment. 2005–2006  

Teaching

5/18-present   Clinical Preceptor, Virtual Gynecologic Oncology Rotation (PGY2 oncology residents)

6/18-present   Clinical Preceptor, Ambulatory Oncology Rotation, Eskenazi Health

12/14-present  PHRM 466, Pharmaceutical Care in Oncology Elective

9/14-present  PHRM 860, Professional Program Laboratory V

9/14-present  PHRM 864, Integrated Pharmacotherapy IV

 

Honors and Credentials

3/20, 1/21   Mortar and Pestle Service Award, Department of Pharmacy Practice, Purdue University College of Pharmacy

3/16    Fellow, Hematology Oncology Pharmacy Association

10/12  Fellow, American College of Clinical Pharmacy

5/11    Purdue College of Pharmacy Faculty Preceptor of the Year

10/05  The Apple Award, “A Salute to Health Care Education,” nominated by patients

Grants

2020  Gloria Niemeyer Francke Pharmacy Practice Advancement Grant Program Award Winner. "Virtually There: An Innovative Approach for Clinical Training for Residents and Students." Awared $7,500.

2011  An Oncology Focused Clinical and Research Experience in Eldoret, Kenya. SAIL Grant Award Winner. Purdue University. $7,000.

 

Clinical Practice

Clinical Pharmacy Specialist-Hematology/Oncology, Eskenazi Health, Indianapolis, IN

Representative Publications

Leidy SB, Hull LR, Macik MR, Gonzalvo JD, Weddle KJ. Retrospective assessment of chemotherapy/biotherapy toxicity in a Hispanic/Latinx population versus published study population. J Oncol Pharm Pract. 2023 Jan;29(1):66-73.

Weddle KJ. Breast Cancer. In CS Zeind, MG Carvalho, eds. Applied Therapeutics. The Clinical Use of Ddrugs. 12th ed. Wolters Kluwer. 2023.

Irene D Lin, Matthew B Shotts, Ahmad Al-Hader, Kellie Jones Weddle, Richard J Holden, Emily L Mueller, Monica Macik, Mirian Ramirez, Ephrem Abebe. Examining adherence to oral anticancer medications through a human factors engineering framework: Protocol for a scoping review. PLoS One. 2022 Sept 22;17(9):e0274963.

Chazan G, Jupp J, Bauters T, Duncan N, Weddle KJ, Nomura H, O'Conner S, Chan A, Alkhudair N, Alshamrani M, Buie LW, Chambers P, Chieh TW, DeRemer DL, Duvivier F, Katabalo D, McFarlane T, Mckanvanagh D, Mensah K, Martinez EM, Rowan G, Sae-teaw M, Tadesse TA, Weru I, Alexander M. Impact of coronavirus of 2019 on the delivery of pharmacy services to patients with cancer. An international survey of oncology pharmacy practitioners. J Oncol Pharm Pract. 2021, October 23. https://doi.org/10/1177/10781552211048892.

Weddle, KJ. Breast Cancer. In Ambulatory Care Self-Assessment Program (ACSAP) by American College of Clinical Pharmacy. 2021.

Weddle KJ, Kiel PJ, Crawford BS, Gass MJ, Smith JA.  Virtually There: An innovative approach for training oncology pharmacy residents in gynecology oncology.  J Am Pharm Assoc. Published: June 26, 2020 DOI: http://doi.org/10.1016/j.japh.2020.06.018.

Dierckes SJ, Ragsdale ME, Macik MR, Weddle KJ. Retrospective analusis of the incidence and severity of acute kidney injury (AKI) in patient with head and neck cancer receiving weekly cisplatin with radiotherapy (RAISe-AKI).  J Oncol Pharm Pract. 2020 Dec 10;1078155220978454. doi: 10.1177/1078155220978454.

Weddle KJ, Kiel PJ, Parth PJ. Assessment of bleeding incidences assoicated with rivaroxaban therapy in adults with solid tumors. J Oncol Pharm Pract. 2019;25(1):192-197. DOI:10.1177/1078155218765635.

Weddle KJ, Kiel P. Drug induced thrombocytopenia. In J Tisdale, D Miller, eds. Drug-Induced Diseases: Prevention, Detection and Management. 3rd ed. Bethesda, MD: American Society of Health System Pharmacists. 2021.

Mach CM, Lapp EA, Weddle KJ, Hunter RJ, Burns KA, Parker C, Brown J, Smith JA. Adjunct histamine blockers as premedications to prevent carboplatin hypersensitivity reactions. Pharmacotherapy. 2016 Mar 15 doi:10.1002/phar.1739. [Epub ahead of print].

Jones KL. Breast cancer. In B Alldredge, R Corelli, M Ernst, B. Joseph Guglielmo, P Jacobson, W Kradjan, B Williams, eds. Applied Therapeutics. The Clinical Use of Drugs. 10th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2013:2197-2209.

Kiel P, Fausel CA, Jones KL.  Testicular germ cell tumors, a history of “if you don’t cure the first time, try, try, again.” J Hematol Oncol Pharm. 2012; 2:85-98.

Jones KL, Barnett C, Gauthier M, Boster B, Espirito JL, Michaud LB.  Clinical outcomes of a pharmacist managed anticoagulation service for breast cancer patients. J Oncol Pharm Pract. 2012; 18(1):122-127.

Jones KL. Cancer screening and prevention. In: Richardson M, Chant C, Chessman KH, Finks SW, Hemstreet BA, Hume AL, et al, eds. Pharmacotherapy Self-Assessment Program, 7th ed. Oncology. Lenexa, KS: American College of Clinical Pharmacy, 2011:7-23.

Pitello N, Treon M, Jones KL, Kiel PJ.  Approaches for administering chemotherapy in the intensive care unit. Curr Drug Saf. 2010; 5(1):22-32.

Jones KL, Buzdar AU. Evolving novel anti-HER2 strategies. Lancet Oncol. 2009; 10:1179-87.

Jones KL, Buzdar A.  A review of adjuvant hormonal therapy in breast cancer.  Endocr Relat Cancer. 2004; 11:391-406.

Michaud LB, Karpinski JP, Jones KL, Espirito J. Dietary supplements in patients with cancer: risks and key concepts, part 1: Am J Health Syst Pharm 2007; 64:369-81.

Navo MA, Phan J, Vaughan C, Palmer JL, Michaud L, Jones KL, Bodurka DC, Basen-Engquist K, Hortobagyi GN, Kavanagh JJ, Smith JA.  An assessment of the utilization of complementary and alternative medications in women with gynecologic or breast malignancies. J Clin Oncol. 2004; Feb 15:671-7.